CONTROLLED RELEASE COMBINATION THERAPY WITH CNP AGONISTS Russian patent published in 2022 - IPC A61K31/505 A61K38/22 A61K38/27 A61K45/06 A61K47/60 A61P19/08 A61P43/00 

FIELD: pharmaceutics.

SUBSTANCE: invention relates to use of a combination of a CNP agonist and human growth hormone in treating or preventing achondroplasia and to methods of treating or preventing a patient suffering such a disorder. Said combination of CNP agonist and growth hormone exhibits synergetic effect consisting in increase of average longitudinal growth of long bones, in particular of femur, and width of endochondral zone / zone of ossification. According to the invention, the CNP agonist is a compound of formula (IIf) or a pharmaceutically applicable salt thereof, where the unmarked dotted line denotes the attachment to the nitrogen atom provided by the lysine side chain at position 26 of the CNP component having the sequence SEQ ID NO: 24 by forming an amide bond; and the dotted line marked with an asterisk denotes attachment to -Z, having the structure indicated in the claims.

(IIf).

EFFECT: treating and preventing achondroplasia using a combination of a CNP agonist and human growth hormone.

23 cl, 2 dwg, 3 tbl, 2 ex